Chimeric Therapeutics is trading 12% up today at A$0.06 after announcing a strategic review and board changes aimed at maximizing shareholder value.
- The company appointed a financial adviser on July 1, 2026, to lead the review and explore potential strategic outcomes.
- Board restructuring, including the retirement of an independent non-executive director, has sparked renewed investor interest and speculation regarding the company's future direction.